Mustang Bio
New York
About Mustang Bio
Mustang Bio is a clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel cancer immunotherapy products designed to utilize the power of the patient's own immune system to eliminate cancer cells. The products under development are - CD123, CD20, and CS1.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $227.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2025)
- Ticker: nasdaq:MBIO
- Website: mustangbio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/mustang-bio-196526 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.